Royalty Pharma plc announced on May 12, 2025, that its shareholders overwhelmingly approved the previously announced acquisition of its external manager, RP Management, LLC. A significant 99.9% of votes cast were in favor of the internalization proposal at the company’s 2025 Annual General Meeting and Special Meeting of Shareholders.
This shareholder approval marks a key milestone for Royalty Pharma's transition from an external manager model to an integrated corporate structure. The transaction is expected to close in May 2025, subject to customary closing conditions, including required regulatory approvals.
The internalization is projected to generate substantial cash savings, with over $100 million expected in 2026 and more than $1.6 billion cumulatively over ten years. This strategic move is also anticipated to strengthen corporate governance, enhance transparency, and further align the leadership team with shareholder interests.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.